Prevention of acute radiation-induced esophagitis with glutamine in non-small cell lung cancer patients treated with radiotherapy: Evaluation of clinical and dosimetric parameters

Lung Cancer

Volumn 63, Issue 3, 2009, Pages 393-399

  Topkan, Erkan ^a   Yavuz, Melek Nur ^a   Onal, Cem ^a   Yavuz, Ali Aydin ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

Acute esophagitis; Glutamine; Lung cancer; Prevention; Radiotherapy; Weight loss

Indexed keywords

GLUTAMINE;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; DOSIMETRY; DRUG EFFICACY; DRUG TOLERABILITY; ESOPHAGITIS; FEMALE; HUMAN; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; MALE; PRESCRIPTION; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RETROSPECTIVE STUDY; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT REDUCTION;

ACUTE DISEASE; ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; DOSE-RESPONSE RELATIONSHIP, RADIATION; ESOPHAGITIS; FEMALE; FOLLOW-UP STUDIES; GLUTAMINE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; RADIATION INJURIES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 59249102479     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.06.015     Document Type: Article

References (47)

1. Belderbos J., Heemsbergen W., Hoogeman M., Pengel K., Rossi M., and Lebesque J. Acute esophageal toxicity in non-small cell lung cancer patients after high dose conformal radiotherapy. Radiother Oncol 75 (2005) 157-164
2. Choy H., Laporte K., Knill-Selby E., Mohr P., and Shyr Y. Esophagitis in combined modality therapy for locally advanced non-small cell lung cancer. Semin Radiat Oncol 9 (1999) 90-96
3. Dillman R.O., Seagren S.L., Propert K.J., Guerra J., Eaton W.L., Perry M.C., et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 323 (1990) 940-945
4. Ahn S.J., Kahn D., Yu X., Hollis D., Shafman T.D., and Marks L.B. Dosimetric and clinical predictors for radiation-induced esophageal injury. Int J Radiat Oncol Biol Phys 61 (2004) 335-347
5. Choy H., Akerley W., Safran H., Graziano S., Chung C., Williams T., et al. Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small cell lung cancer. J Clin Oncol 16 (1998) 3316-3322
6. Chapet O., Kong F.M., Lee J.S., Hayman J.A., and Ten Haken R.K. Normal tissue complication probability modeling for acute esophagitis in patients treated with conformal radiation therapy for non-small cell lung cancer. Radiother Oncol 77 (2005) 176-181
7. Qiao W.B., Zhao Y.H., Zhao Y.B., and Wang Z.B. Clinical and dosimetric factors of radiation-induced esophageal injury: radiation-induced esophageal toxicity. World J Gastroenterol 11 (2005) 2626-2629
8. Takeda K., Nemoto K., Satto H., Ogawa Y., Takai Y., and Yamada S. Predictive factors for acute esophageal toxicity in thoracic radiotherapy. Tohoku J Exp Med 208 (2006) 299-306
9. Movsas B., Scott C., Langer C., Werner-Wasik M., Nicolaou N., Komaki R., et al. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: Radiation Therapy Oncology Group Trial 98-01. J Clin Oncol 23 (2005) 2145-2154
10. Antonadou D., Throuvalas N., Petridis A., Bolanos N., Sagriotis A., and Synodinou M. Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 57 (2003) 402-408
11. Bartlett D., Charland S., and Torosian M. Effect of glutamine on tumor and host growth. Ann Surg Oncol 2 (1995) 71-76
12. Klimberg V., Souba W.W., Dolson D.J., Salloum R.M., Hautamaki R.M., Mendenhall W.R., et al. Prophylactic glutamine protects the intestinal mucosa from radiation injury. Cancer 66 (1990) 62-68
13. Souba W.W., and Wilmore D.S. Postoperative alteration of arteriovenous exchange of amino acids across the gastrointestinal tract. Surgery 94 (1983) 342-350
14. Kapadia C., Muhlbacher F., and Smith R. Alterations in glutamine metabolism in response to operative stress and food deprivation. Surg Forum 33 (1982) 19-21
15. Savarese D.M., Savy G., Vahdat L., Wischmeyer P.E., and Corey B. Prevention of chemotherapy and radiation toxicity with glutamine. Cancer Treat Rev 29 (2003) 501-513
16. Rouse K., Nwokedi E., Woodliff J., Epstein J., and Klimberg V.S. Glutamine enhances selectivity of chemotherapy through changes in glutathione metabolism. Ann Surg 221 (1995) 420-426
17. Klimberg V.S., Nwokedi B., and Hutchins L.F. Does glutamine facilitate chemotherapy while reducing its toxicity?. Surg Forum 42 (1991) 16-18
18. Carretero J., Obrador E., Pellicer J.A., Pascual A., and Estrala J.M. Mitochondrial glutathione depletion by glutamine in growing tumor cells. Free Radic Biol Med 29 (2000) 913-923
19. Klimberg V., Souba W., and Salloum R. Glutamine-enriched diets support muscle glutamine metabolism without stimulating tumor growth. J Surg Res 48 (1990) 319-323
20. Rodrigues G., Lock M., D'Souza D., Yu E., and Van Dyk J. Prediction of radiation pneumonitis by dose-volume histogram parameters in lung cancer. A systematic review. Radiother Oncol 71 (2004) 127-138
21. Metha V. Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung cancer: pulmonary function, prediction, and prevention. Int J Radiat Oncol Biol Phys 63 (2005) 5-24
22. Cox J.D., Stez J., and Pajak T.F. Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys 31 (1995) 1341-1346
23. Singh A.K., Lockett M.A., and Bradley J.D. Predictors of radiation-induced esophageal toxicity in patients with non-small lung cancer treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 55 (2003) 337-341
24. Werner-Wasik M., Pequignot E., Leeper D.S., Hauck W., and Curran W. Predictors of severe esophagitis include use of concurrent chemotherapy, but not the length of irradiated esophagus: a multivariate analysis of patients with lung cancer treated with nonoperative therapy. Int J Radiat Oncol Biol Phys 48 (2000) 689-696
25. Rosenman J.G., Halle J.S., Socinski M.A., Deschesne K., Moore D.T., Johnson H., et al. High-dose conformal radiotherapy for treatment of stage IIIA/IIIB nonsmall-cell lung cancer: technical issues and results of a Phase I/II trial. Int J Radiat Oncol Biol Phys 54 (2002) 348-356
26. Langer C.J., Movsas B., Hudes R., Schol J., Keennan E., Kilpatrick D., et al. Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: Report of Fox Chase Cancer Center Study 94-001. Semin Oncol 24 Suppl. 12 (1997) 12-95
27. Kim T.H., Cho K.H., Pyo H.R., Lee J.S., Han J.Y., Zo J.I., et al. Dose-volumetric parameters of acute esophageal toxicity in patients with lung cancer treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 62 (2005) 995-1002
28. Emami B., Lyman J., Brown A., Coia L., Goitein M., Munzenrider J.E., et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21 (1991) 109-122
29. Maguire P.D., Sibley G.S., Zhou S.M., Jamieson T.E., Light K.L., Antoine P.A., et al. Clinical and dosimetric predictors of radiation-induced esophageal toxicity. Int J Radiat Oncol Biol Phys 45 (1999) 97-103
30. Bradley J., Deasy J.O., Bentzen S., and El-Naka I. Dosimetric correlates for acute esophagitis in patients treated with radiotherapy for lung carcinoma. Int J Radiat Oncol Biol Phys 61 (2005) 1106-1113
31. Algara M., Rodriguez N., Vinals P., Lacruz M., Foro P., and Reig A. Prevention of radiochemotherapy-induced esophagitis with glutamine: results of a pilot study. Int J Radiat Oncol Biol Phys 69 (2007) 342-349
32. Sause W., Kolesar P., Taylor IV S., Johnson D., Livingston R., Komaki R., et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 117 (2000) 358-364
33. Klimberg V. How glutamine protects the gut during irradiation. J Crit Care Nutr 3 (1996) 21-25
34. Souba W.W., Klimberg V.S., Hautamaki R.D., Mendenhall W.H., Bova F.C., Howard R.J., et al. Oral glutamine reduces bacterial translocation following abdominal irradiation. J Surg Res 48 (1990) 1-5
35. Salman B., Oguz M., Akmansu M., Bebitoglu I., Akca G., Sultan N., et al. Effect of timing of glutamine-enriched enteral nutrition on intestinal damage caused by irradiation. Adv Ther 24 3 (2007) 648-661
36. Huang E.Y., Wan Leung S., Wang C.J., Chen H.C., Sun L.M., Fang F.M., et al. Oral glutamineto alleviate radiation-induced oral mucositis: a pilot randomized trial. Int J Radiat Oncol Biol Phys 46 (2000) 9-535
37. Yoshida S., Matsui M., Shirouzu Y., Fujita H., Yamana H., and Shirouzu K. Effects of glutamine supplements and radiochemotherapy on systemic immune and gut barrier function in patients with advanced esophageal cancer. Ann Surg 227 4 (1998) 485-491
38. Cerchietti L.C., Navigante A.H., Lutteral M.A., Castro M.A., Kirchuk R., Boromi M., et al. Double-blind, placebo-controlled trial on intravenous l-alanyl-l-glutamine in the incidence of oral mucositis following chemoradiotherapy in patients with head-and-neck cancer. Int J Radiat Oncol Biol Phys 65 (2006) 1330-1337
39. Inui A. Cancer anorexia-cachexia syndrome. Current issues in research and management. CA Cancer J Clin 52 (2002) 72-91
40. Stanley K.E. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 65 (1980) 25-32
41. Werner-Wasik M., Scott C., Cox J.D., Sause W.T., Byhardt R.W., Asbell S., et al. Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally advanced non-small-cell lung cancer (LANSCLC); identification of five groups with different survival. Int J Radiat Oncol Biol Phys 48 (2000) 1475-1482
42. Nixon D.W., Heymsfield S.B., Cohen A.E., Kutner M.H., Ansley J., Lawson D.H., et al. Protein-calorie under nutrition in hospitalized cancer patients. Am J Med 68 (1980) 683-690
43. May P.E., Barber A., D'Olimpio J.T., Hourihane A., and Abumrad N.N. Reversal of cancer-related wasting using oral supplementation with a combination of β-hydroxy-β-methybutyrate, arginine, and glutamine. Am J Surg 183 (2002) 471-479
44. Patel A.B., Edelman M.J., Kwok Y., Krasna M.J., and Suntharalingam M. Predictors of acute esophagitis in patients with non-small cell lung carcinoma treated with concurrent chemotherapy and hyperfractionated radiotherapy followed by surgery. Int J Radiat Oncol Biol Phys 60 (2004) 1106-1112
45. Chen M.K., Salloum R.M., Austgen T.R., Bland J.B., Bland K.I., Copeland E.M., et al. Tumor regulation of hepatic glutamine metabolism. JPEN J Parenter Enteral Nutr 15 (1991) 159-164
46. Ziegler T., Benfell K., Smith R.J., Young L.S., Brown E., Ferrari-Baliviera E., et al. Safety and metabolic effects of l-glutamine administration in humans. JPEN J Parenter Enteral Nutr 14 (1990) 137-146
47. Anderson P.M., Schroeder G., and Skubitz K.M. Oral glutamine reduces the duration and severity of stomatitis after cytotoxic cancer chemotherapy. Cancer 83 (1998) 1433-1439